$ABTI
ALTEROLA BIOTECH INC. Stock $abti

$abti Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000166357724000238 Filed on August 15, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$428.2K	$590.0K
YoY Change		-27.42%	208.05%
% of Gross Profit
Research & Development	$16.96K	$19.14K
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$477.2K	$447.4K	$580.7K
YoY Change	287.5%	-22.96%	176.51%
Operating Profit	-$477.2K	-$447.4K	-$580.7K
YoY Change	287.5%	-22.96%	176.51%
Interest Expense	$337.3K	$28.08K	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$322.0K	$28.08K	-$138.2K
YoY Change	161.43%	-120.32%
Pretax Income		-$419.3K	-$730.0K
YoY Change		-42.56%	247.62%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$799.2K	-$419.3K	-$718.8K
YoY Change	548.93%	-41.67%	242.3%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share		$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	1.460B shares	1.467B shares	807.0M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments		$10.96K	$40.00K
YoY Change		-72.6%	-35.0%
Cash & Equivalents	$82.72K	$10.96K	$36.55K
Short-Term Investments
Other Short-Term Assets			$190.0K
YoY Change			331.52%
Inventory	$1.069K	$1.011K	$1.009K
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$1.147M	$11.97K	$231.2K
YoY Change	481.63%	-94.82%	93.71%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$217.0K	$0.00	$12.46M
YoY Change	-27.65%	-100.0%	3.85%
TOTAL ASSETS
Total Short-Term Assets	$1.147M	$11.97K	$231.2K
Total Long-Term Assets	$217.0K	$0.00	$12.46M
Total Assets	$1.364M	$11.97K	$12.69M
YoY Change	174.35%	-99.91%	4.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$805.3K	$865.7K	$678.0K
YoY Change	11.52%	27.69%	18.84%
Accrued Expenses	$462.0K	$490.2K	$283.1K
YoY Change	87.52%	73.12%	-30.32%
Deferred Revenue
YoY Change
Short-Term Debt		$151.8K	$1.370M
YoY Change		-88.92%	1275.92%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.615M	$1.508M	$2.334M
YoY Change	43.51%	-35.41%	116.84%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities		$0.00	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.615M	$1.508M	$2.334M
Total Long-Term Liabilities		$0.00	$0.00
Total Liabilities	$3.615M	$1.508M	$2.334M
YoY Change	43.51%	-35.41%	90.07%
SHAREHOLDERS EQUITY
Retained Earnings	-$13.67M	-$12.84M	-$10.30M
YoY Change	31.09%	24.67%	25.85%
Common Stock	$1.467M	$1.467M	$807.0K
YoY Change	88.61%	81.83%	0.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.055M	-$1.496M	$10.36M
YoY Change
Total Liabilities & Shareholders Equity	$1.364M	$11.97K	$12.69M
YoY Change	174.35%	-99.91%	4.73%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	-$799.2K	-$419.3K	-$718.8K
YoY Change	548.93%	-41.67%	242.3%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities		$55.56K	-$75.47K
YoY Change		-173.62%	-54.52%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$20.00K
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities			-$18.90K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		$6.144K	$68.45K
YoY Change		-91.02%	6122.64%
NET CHANGE
Cash From Operating Activities		$55.56K	-$75.47K
Cash From Investing Activities			-$18.90K
Cash From Financing Activities		$6.144K	$68.45K
Net Change In Cash		$61.71K	-$25.92K
YoY Change		-338.08%	1039.75%
FREE CASH FLOW
Cash From Operating Activities		$55.56K	-$75.47K
Capital Expenditures		$0.00	$20.00K
Free Cash Flow		$55.56K	-$95.47K
YoY Change		-158.2%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2024Q2	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2025
CY2024Q2	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q2	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2024Q2	dei	Entity Central Index Key EntityCentralIndexKey	0001442999
CY2024Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
CY2024Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q2	us-gaap	Revenues Revenues		usd
CY2023Q2	us-gaap	Revenues Revenues		usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
CY2023Q2	us-gaap	Legal Fees LegalFees		usd
CY2024Q2	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees		usd
CY2024Q2	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax		usd
CY2023Q2	ABTI	Foreign Exchange Influences ForeignExchangeInfluences		usd
CY2024Q2	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	97641144	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued		usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2024Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2024Q2	us-gaap	Payments For Purchase Of Other Assets1 PaymentsForPurchaseOfOtherAssets1		usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2024Q2	ABTI	Shares Issued To Directors SharesIssuedToDirectors		usd
CY2024Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions		usd
CY2024Q2	ABTI	Shares Issued For Exercise Of Warrants SharesIssuedForExerciseOfWarrants		usd
CY2024Q2	ABTI	Shares Issued For Conversion Of Notes Payable SharesIssuedForConversionOfNotesPayable		usd
CY2023Q2	ABTI	Shares Issued For Back Wages SharesIssuedForBackWages		usd
CY2024Q2	dei	Document Type DocumentType	10-Q
CY2024Q2	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q2	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
CY2024Q2	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q2	dei	Entity File Number EntityFileNumber	333-156091
CY2024Q2	dei	Entity Registrant Name EntityRegistrantName	Alterola Biotech, Inc.
CY2024Q2	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2024Q2	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-1317032
CY2024Q2	dei	Entity Address Address Line1 EntityAddressAddressLine1	47 Hamilton Square
CY2024Q2	dei	Entity Address City Or Town EntityAddressCityOrTown	Birkenhead Merseyside
CY2024Q2	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	CH41 5AR
CY2024Q2	dei	Entity Address Country EntityAddressCountry	GB
CY2024Q2	dei	City Area Code CityAreaCode	151
CY2024Q2	dei	Local Phone Number LocalPhoneNumber	601 9477
CY2024Q2	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q2	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q2	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q2	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q2	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q2	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1459502018	shares
CY2024Q2	us-gaap	Cash Cash	10955	usd
CY2024Q1	us-gaap	Cash Cash	2654	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	1011	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	1009	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	11966	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	3663	usd
CY2024Q2	us-gaap	Assets Assets	11966	usd
CY2024Q1	us-gaap	Assets Assets	3663	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	865724	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	825210	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	490164	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	362451	usd
CY2024Q2	us-gaap	Loans Payable Current LoansPayableCurrent	151747	usd
CY2024Q1	us-gaap	Loans Payable Current LoansPayableCurrent	145603	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1507635	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1333264	usd
CY2024Q2	us-gaap	Liabilities Liabilities	1507635	usd
CY2024Q1	us-gaap	Liabilities Liabilities	1333264	usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1467475449	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1467475449	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1382662952	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1382662952	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	1467484	usd
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	1382663	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	9885765	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	9663951	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-12835373	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-12416075	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-13545	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	39860	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-1495669	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-1329601	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11966	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3663	usd
CY2024Q2	ABTI	Accounting And Audit Fees AccountingAndAuditFees	79930	usd
CY2023Q2	ABTI	Accounting And Audit Fees AccountingAndAuditFees	48938	usd
CY2024Q2	us-gaap	Professional Fees ProfessionalFees	2301	usd
CY2023Q2	us-gaap	Professional Fees ProfessionalFees	5290	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19135	usd
CY2024Q2	us-gaap	Legal Fees LegalFees	281	usd
CY2023Q2	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	171000	usd
CY2024Q2	ABTI	Consulting Fees ConsultingFees	289058	usd
CY2023Q2	ABTI	Consulting Fees ConsultingFees	317741	usd
CY2024Q2	us-gaap	Salaries And Wages SalariesAndWages	43663	usd
CY2023Q2	us-gaap	Salaries And Wages SalariesAndWages	35939	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13005	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6292	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	447373	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	585200	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-447373	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-585200	usd
CY2023Q2	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	138163	usd
CY2024Q2	ABTI	Foreign Exchange Influences ForeignExchangeInfluences	28075	usd
CY2024Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	28075	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	138163	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-419298	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-447037	usd
CY2024Q2	ABTI	Income Loss From Continuing Operations Per Basic IncomeLossFromContinuingOperationsPerBasic	-0.00
CY2023Q2	ABTI	Income Loss From Continuing Operations Per Basic IncomeLossFromContinuingOperationsPerBasic	-0.00
CY2024Q2	ABTI	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	1429742622	shares
CY2023Q2	ABTI	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	807047948	shares
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-419298	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-447037	usd
CY2024Q2	ABTI	Foreign Translation Adjustment ForeignTranslationAdjustment	-53405	usd
CY2023Q2	ABTI	Foreign Translation Adjustment ForeignTranslationAdjustment	-77779	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-472703	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-524816	usd
CY2023Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-77779	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	157339	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	295000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	305672	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	171000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-447037	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	10165339	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-1329601	usd
CY2024Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-53405	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	74000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	28935	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	203700	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-419298	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-1495669	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-419298	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-447037	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	203700	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	305672	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	74000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	171000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	157339	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	28935	usd
CY2024Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2	usd
CY2023Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-19	usd
CY2024Q2	ABTI	Increase Decrease In Vat Taxes Receivable IncreaseDecreaseInVATTaxesReceivable	28684	usd
CY2023Q2	ABTI	Increase Decrease In Vat Taxes Receivable IncreaseDecreaseInVATTaxesReceivable	36426	usd
CY2024Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	11830	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	64259	usd
CY2024Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	127713	usd
CY2023Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	23181	usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	55562	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	310821	usd
CY2023Q2	us-gaap	Payments For Purchase Of Other Assets1 PaymentsForPurchaseOfOtherAssets1	-166852	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-166852	usd
CY2024Q2	us-gaap	Increase Decrease In Notes Payable Related Parties IncreaseDecreaseInNotesPayableRelatedParties	6144	usd
CY2023Q2	us-gaap	Increase Decrease In Notes Payable Related Parties IncreaseDecreaseInNotesPayableRelatedParties	-38535	usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6144	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-38535	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	61706	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	105434	usd
CY2024Q2	us-gaap	Foreign Currency Transaction Gain Loss Excluding Investment Price Change After Tax ForeignCurrencyTransactionGainLossExcludingInvestmentPriceChangeAfterTax	-53405	usd
CY2023Q2	us-gaap	Foreign Currency Transaction Gain Loss Excluding Investment Price Change After Tax ForeignCurrencyTransactionGainLossExcludingInvestmentPriceChangeAfterTax	-77779	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2654	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8890	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10955	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36545	usd
CY2024Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	277700	usd
CY2023Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	305762	usd
CY2023Q2	ABTI	Shares Issued To Directors SharesIssuedToDirectors	171000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	295000	usd
CY2023Q2	ABTI	Shares Issued For Exercise Of Warrants SharesIssuedForExerciseOfWarrants	13500	usd
CY2023Q2	ABTI	Shares Issued For Conversion Of Notes Payable SharesIssuedForConversionOfNotesPayable	157339	usd
CY2024Q2	ABTI	Shares Issued For Back Wages SharesIssuedForBackWages	28935	usd
CY2024Q2	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_808_eus-gaap--NatureOfOperations_zYkJmOrjdofk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 1 – NATURE OF BUSINESS, LIQUIDITY & GOING CONCERN</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify">After formation, the Company was in the business of mineral exploration. On May 3, 2010, the Company sold its mineral exploration business and entered into an Intellectual Property Assignment Agreement (“IP Agreement”) with Soren Nielsen pursuant to which Mr. Nielsen transferred his right, title and interest in all intellectual property relating to certain chewing gum compositions having appetite suppressant activity (the “IP”) to the Company for the issuance of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20100503__20100503__us-gaap--StatementEquityComponentsAxis__custom--IssuanceOneMember_zadS9Pasc7v4">55,000,000</span> shares of the Company’s common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify">Following the acquisition of the IP the Company changed its business direction to pursue the development of chewing gums for the delivery of Nutraceutical/functional ingredients for applications such as appetite suppressant, cholesterol suppressant, vitamin delivery, antioxidant delivery and motion sickness suppressant.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 19, 2021, the Company entered into a Stock Purchase Agreement (the “Agreement”) with ABTI Pharma Limited, a company registered in England and Wales (“ABTI Pharma”), pursuant to which the Company agreed to acquire all of the outstanding shares of capital stock of ABTI Pharma from its shareholders in exchange for <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20210119__20210119__us-gaap--StatementEquityComponentsAxis__custom--IssuanceTwoMember_zdrS0teJ2pw4">600,000,000</span> shares of the Company pro rata to the ABTI Pharma shareholders. The shares were issued on January 29, 2021 in anticipation of the closing and the parties to the transaction agreed in a March 24, 2021 amendment to close upon the ABTI Pharma Limited Shares being transferred to the Company, which was to occur upon the filing by the Company of its outstanding September 30, 2020 quarterly report on Form 10-Q, which was filed on May 28, 2021 with the Securities and Exchange Commission. The transaction closed on May 28, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The transaction was accounted for as a reverse acquisition and recapitalization. ABTI Pharma is the acquirer for accounting purposes and the Company is the issuer. The historical financial statements presented are the financial statements of ABTI. The Agreement was treated as a recapitalization and not as a business combination; at the date of the acquisition, the net liabilities of the legal acquirer, Alterola, were <span id="xdx_901_eus-gaap--Liabilities_iI_pp0p0_c20210528_zMrGZ2wlpwj6">$389,721</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The business plan of the company is no longer focused on a chewing gum delivery system but was re-focused on the development of cannabinoid, cannabinoid-like, and non-cannabinoid pharmaceutical active pharmaceutical ingredients (APIs), pharmaceutical medicines made from cannabinoid, cannabinoid-like, and non-cannabinoid APIs and European novel food approval of cannabinoid-based, cannabinoid-like and non-cannabinoid ingredients and products. In addition, the company plans to develop such bulk ingredients for supply into the cosmetic sector.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 2, 2021, the Company closed an Asset Purchase Agreement (the “Purchase Agreement”) with C2 Wellness Corp., a Wyoming corporation, and Dr. G. Sridhar Prasad (together, the “Seller”) and acquired certain IP assets (the “Assets”) from Seller, which include:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 4%"> </td> <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">•</span></td> <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Novel cannabinoid molecules and their associated intellectual property;</span></td></tr> </table> <p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 4%"> </td> <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">•</span></td> <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Novel cannabinoid pro-drugs, and their associated intellectual property;</span></td></tr> </table> <p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 4%"> </td> <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">•</span></td> <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Novel proprietary cannabinoid formulations, designed to target lymphatic delivery, and their associated intellectual property;</span></td></tr> </table> <p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 4%"> </td> <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">•</span></td> <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Novel proprietary nano-encapsulated cannabinoid formulations, in self-dissolving polymers, and their associated intellectual property; and</span></td></tr> </table> <p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 4%"> </td> <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">•</span></td> <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cannabinoids and cannabinoid pro-drug formulations for topical ocular delivery, and their associated intellectual property.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ALTEROLA BIOTECH, INC.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>JUNE 30, 2024</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In exchange for the Assets, the Company issued to Seller shares of common stock. On September 8, 2023, the Company and Seller entered into an Agreement to sell the assets, such that the Company sold the assets back to the Seller and the Seller paid <span id="xdx_90E_eus-gaap--StockRepurchasedDuringPeriodShares_c20230908__20230908__us-gaap--StatementEquityComponentsAxis__custom--C2WellnessAgreementReturnAssetsMember_zAsUll0XCAJ6">29,015,993</span> shares of ABTI common stock to the Company. The assets were sold to the Seller in September 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of April 18, 2023, we acquired intellectual property from Alinova Biosciences Ltd. We acquired Alinova’s joint interest in the patent family of PTX 0001. We paid <span id="xdx_905_eus-gaap--AcquisitionCosts_c20230418__20230418__us-gaap--AssetAcquisitionAxis__custom--PatentPTXMember_zeozBWgYmuJ">35,000</span> Sterling in cash and <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20230418__20230418__us-gaap--AssetAcquisitionAxis__custom--PatentPTXMember_zrmffJ8QqTHa">5,000,000</span> shares of ABTI Stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 16, 2024, the Company formed a new subsidiary Phytanix Bio.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84E_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zWo1t5cCGGp7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>LIQUIDITY & GOING CONCERN</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Alterola has negative working capital of <span id="xdx_90D_eus-gaap--Capital_iNI_di_c20240630_zEi6VFdkDKT2">$1,495,669</span>, has incurred losses since inception of <span id="xdx_90C_eus-gaap--ProfitLoss_iN_pp0p0_di_c20091016__20240630_zjHpsKxPlu5k">$12,837,659</span>, and has not received revenues from sales of products or services. These factors create substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The ability of Alterola to continue as a going concern is dependent on the Company generating cash from the sale of its common stock and/or obtaining debt financing and attaining future profitable operations. Management’s plans include selling its equity securities and obtaining debt financing to fund its capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts.</p> <p id="xdx_85E_zVS1fDaQzci8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p>
CY2021Q2	us-gaap	Liabilities Liabilities	389721	usd
CY2024Q2	us-gaap	Capital Capital	-1495669	usd
	us-gaap	Profit Loss ProfitLoss	-12837659	usd
CY2024Q2	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84C_eus-gaap--UseOfEstimates_zQaAOaNb4qHc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Use of Estimates</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
CY2024Q2	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	392278	usd
CY2024Q2	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zjtYNdNRPh7g" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Risks and Uncertainties</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 30, 2020, the World Health Organization declared the coronavirus outbreak a “Public Health Emergency of International Concern” and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the coronavirus include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and business. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may be impacted by business interruptions resulting from pandemics and public health emergencies, including those related to geopolitical actions, including war and terrorism or natural disasters including earthquakes, typhoons, floods, and fires. An outbreak of infectious disease, a pandemic or a similar public health threat or a fear of any of the foregoing, could adversely impact us by causing operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how we may be affected if such an epidemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results, and financial condition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
CY2021Q4	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	12000000	usd
CY2024Q1	ABTI	Intangible Assets Current Adjusted IntangibleAssetsCurrentAdjusted	12139779	usd
CY2023Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	189355	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	865724	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	825210	usd
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	12000000	usd
CY2023Q2	us-gaap	Stock Issued During Period Shares Treasury Stock Reissued StockIssuedDuringPeriodSharesTreasuryStockReissued	44064000	shares
CY2024Q2	us-gaap	Contract With Customer Asset Allowance For Credit Loss Writeoff ContractWithCustomerAssetAllowanceForCreditLossWriteoff	12000000	usd
CY2023Q4	ABTI	Loss On Exchange Of Shares For Debt LossOnExchangeOfSharesForDebt	406575	usd
CY2023Q2	ABTI	Translation Amended Amount TranslationAmendedAmount	67873	usd
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1467475449	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1467475449	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1382662952	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1382662952	shares
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	807047948	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	807047948	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	807047948	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	807047948	shares
CY2024Q2	ABTI	Shareholder Advances ShareholderAdvances	6144	usd

Files In Submission

Name	View Source	Status
0001663577-24-000238-index-headers.html	Edgar Link	pending
0001663577-24-000238-index.html	Edgar Link	pending
0001663577-24-000238.txt	Edgar Link	pending
0001663577-24-000238-xbrl.zip	Edgar Link	pending
abti-20240630.xsd	Edgar Link	pending
abti10q1_063024.htm	Edgar Link	pending
ex10_1.htm	Edgar Link	pending
ex10_2.htm	Edgar Link	pending
ex10_3.htm	Edgar Link	pending
ex2_1.htm	Edgar Link	pending
ex31_1.htm	Edgar Link	pending
ex31_2.htm	Edgar Link	pending
ex32_1.htm	Edgar Link	pending
ex4_1.htm	Edgar Link	pending
ex4_2.htm	Edgar Link	pending
ex4_3.htm	Edgar Link	pending
ex4_4.htm	Edgar Link	pending
ex4_5.htm	Edgar Link	pending
ex4_6.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
abti-20240630_lab.xml	Edgar Link	unprocessable
abti-20240630_pre.xml	Edgar Link	unprocessable
abti10q1_063024_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
abti-20240630_cal.xml	Edgar Link	unprocessable
abti-20240630_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABTI
ALTEROLA BIOTECH INC. Stock $abti

2024 Q3 Form 10-Q Financial Statement

#000166357724000238 Filed on August 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABTI ALTEROLA BIOTECH INC. Stock $abti

2024 Q3 Form 10-Q Financial Statement

#000166357724000238 Filed on August 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABTI
ALTEROLA BIOTECH INC. Stock $abti